The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Combination pharmacotherapy for the treatment of neuropathic pain in adults
Open accessAbstract
BACKGROUND: Pharmacotherapy remains an important modality for the treatment of neuropathic pain. However, as monotherapy current drugs are associated with limited efficacy and dose-related side effects. Combining two or more different drugs may improve analgesic efficacy and, in some situations, reduce overall side effects (e.g. if synergistic interactions allow for dose reductions of combined drugs). OBJECTIVES: This review evaluated the efficacy, tolerability and safety of various drug combinations for the treatment of neuropathic pain. SEARCH METHODS: We identified randomised controlled trials (RCTs) of various drug combinations for neuropathic pain from CENTRAL, MEDLINE, EMBASE and handsearches of other reviews and trial registries. The most recent search was performed on 9 April 2012. SELECTION CRITERIA: Double-blind, randomised studies comparing combinations of two or more drugs (systemic or topical) to placebo and/or at least one other comparator for the treatment of neuropathic pain. DATA COLLECTION AND ANALYSIS: Data extracted from each study included: proportion of participants a) reporting ≥ 30% pain reduction from baseline OR ≥ moderate pain relief OR ≥ moderate global improvement; b) dropping out of the trial due to treatment-emergent adverse effects; c) reporting each specific adverse effect (e.g. sedation, dizziness) of ≥ moderate severity. The primary comparison of interest was between study drug(s) and one or both single-agent comparators. We combined studies if they evaluated the same drug class combination at roughly similar doses and durations of treatment. We used RevMan 5 to analyse data for binary outcomes. MAIN RESULTS: We identified 21 eligible studies: four (578 participants) evaluated the combination of an opioid with gabapentin or pregabalin; two (77 participants) evaluated an opioid with a tricyclic antidepressant; one (56 participants) of gabapentin and nortriptyline; one (120 participants) of gabapentin and alpha-lipoic acid, three (90 participants) of fluphenazine with a tricyclic antidepressant; three (90 participants) of an N-methyl-D-aspartate (NMDA) blocker with an agent from a different drug class; five (604 participants) of various topical medications; one (313 participants) of tramadol with acetaminophen; and another one (44 participants) of a cholecystokinin blocker (L-365,260) with morphine. The majority of combinations evaluated to date involve drugs, each of which share some element of central nervous system (CNS) depression (e.g. sedation, cognitive dysfunction). This aspect of side effect overlap between the combined agents was often reflected in similar or higher dropout rates for the combination and may thus substantially limit the utility of such drug combinations. Meta-analysis was possible for only one comparison of only one combination, i.e. gabapentin + opioid versus gabapentin alone. This meta-analysis involving 386 participants from two studies demonstrated modest, yet statistically significant, superiority of a gabapentin + opioid combination over gabapentin alone. However, this combination also produced significantly more frequent side effect-related trial dropouts compared to gabapentin alone. AUTHORS' CONCLUSIONS: Multiple, good-quality studies demonstrate superior efficacy of two-drug combinations. However, the number of available studies for any one specific combination, as well as other study factors (e.g. limited trial size and duration), preclude the recommendation of any one specific drug combination for neuropathic pain. Demonstration of combination benefits by several studies together with reports of widespread clinical polypharmacy for neuropathic pain surely provide a rationale for additional future rigorous evaluations. In order to properly identify specific drug combinations which provide superior efficacy and/or safety, we recommend that future neuropathic pain studies of two-drug combinations include comparisons with placebo and both single-agent components. Given the apparent adverse impact of combining agents with similar adverse effect profiles (e.g. CNS depression), the anticipated development and availability of non-sedating neuropathic pain agents could lead to the identification of more favourable analgesic drug combinations in which side effects are not compounded.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., Cleeland, C., Dionne, R., Farrar, J. T., Galer, B. S., et al. (2003) · Pain · doi:10.1016/j.pain.2003.08.001 · Cited by 3,510
Greenhalgh, T., & Peacock, R. (2005) · BMJ · doi:10.1136/bmj.38636.593461.68 · Cited by 2,045
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Prevalence of chronic pain with neuropathic characteristics in the general population
Bouhassira, D., Lantéri-Minet, M., Attal, N., Laurent, B., & Touboul, C. (2008) · Pain · doi:10.1016/j.pain.2007.08.013 · Cited by 1,745
A new definition of neuropathic pain
Jensen, T. S., Baron, R., Haanpää, M., Kalso, E., Loeser, J. D., Rice, A. S. C., & Treede, R.-D. (2011) · Pain · doi:10.1016/j.pain.2011.06.017 · Cited by 1,427
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,330
Meta-Analysis in Clinical Research
L'ABBÉ, K. A., DETSKY, A. S., & O'ROURKE, K. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-224 · Cited by 1,267
Cited by
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Self-citationDiabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Gabapentin for chronic neuropathic pain in adults
Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S., Tölle, T. R., Phillips, T., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub4 · Cited by 561
Self-citationManagement of Musculoskeletal Pain: An Update with Emphasis on Chronic Musculoskeletal Pain
El-Tallawy, S. N., Nalamasu, R., Salem, G. I., LeQuang, J. A. K., Pergolizzi, J. V., & Christo, P. J. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00235-2 · Cited by 532
Moulin, D., Boulanger, A., Clark, A., Clarke, H., Dao, T., Finley, G., Furlan, A., Gilron, I., Gordon, A., Morley-Forster, P., et al. (2014) · Pain Research and Management · doi:10.1155/2014/754693 · Cited by 529
Self-citationA Comprehensive Algorithm for Management of Neuropathic Pain
Bates, D., Schultheis, B. C., Hanes, M. C., Jolly, S. M., Chakravarthy, K. V., Deer, T. R., Levy, R. M., & Hunter, C. W. (2019) · Pain Medicine · doi:10.1093/pm/pnz075 · Cited by 401
Flatters, S. J. L., Dougherty, P. M., & Colvin, L. A. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex229 · Cited by 391
Pregabalin for neuropathic pain in adults
Derry, S., Bell, R. F., Straube, S., Wiffen, P. J., Aldington, D., & Moore, R. A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub3 · Cited by 364
Self-citationChallenges of neuropathic pain: focus on diabetic neuropathy
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R.-D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02145-7 · Cited by 325
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews
Wiffen, P. J., Derry, S., Moore, R. A., Aldington, D., Cole, P., Rice, A. S., Lunn, M. P., Hamunen, K., Haanpaa, M., & Kalso, E. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010567.pub2 · Cited by 306
Self-citationAviram, J. (2017) · Pain Physician · doi:10.36076/ppj.20.5.e755 · Cited by 305
Els, C., Jackson, T. D., Kunyk, D., Lappi, V. G., Sonnenberg, B., Hagtvedt, R., Sharma, S., Kolahdooz, F., & Straube, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012509.pub2 · Cited by 284
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data
Andreae, M. H., Carter, G. M., Shaparin, N., Suslov, K., Ellis, R. J., Ware, M. A., Abrams, D. I., Prasad, H., Wilsey, B., Indyk, D., et al. (2015) · The Journal of Pain · doi:10.1016/j.jpain.2015.07.009 · Cited by 266
Pharmacotherapy for Neuropathic Pain: A Review
Fornasari, D. (2017) · Pain and Therapy · doi:10.1007/s40122-017-0091-4 · Cited by 258
Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management
Watson, J. C., & Dyck, P. J. B. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.05.004 · Cited by 258
Single dose oral ibuprofen plus paracetamol (acetaminophen) for acute postoperative pain
Derry, C. J., Derry, S., & Moore, R. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010210.pub2 · Cited by 173
Self-citationMultimodal Treatment of Chronic Pain
Dale, R., & Stacey, B. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.08.012 · Cited by 171
Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., Galloway, K., & Namaka, M. (2015) · Pain Medicine · doi:10.1111/pme.12569 · Cited by 124
A systematic review: mindfulness intervention for cancer-related pain
Ngamkham, S., Holden, J. E., & Smith, E. L. (2019) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_67_18 · Cited by 103
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Bulaj, G. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00126 · Cited by 29
Metadata
- Authors
- Chaparro, L. E., Wiffen, P. J., Moore, R. A., & Gilron, I.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-07-11
- Volume
- 2020
- Issue
- 7
- Pages
- CD008943-CD008943
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2005625267
- Cited by
- 310
- References
- 111
- FWCI
- 17.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.